Company reports third death in SL-401 trial

In stage 1, two BPDCN patients had CLS—one grade 5 (7 μg/kg) and one grade 4 (12 μg/kg). After this, safety precautions were implemented to minimize the risk of severe CLS.

A second CLS-related death occurred in stage 1 in a patient with relapsed/refractory AML (16 μg/kg).

The other death in a BPDCN patient with CLS was reported after the ASH presentation. Stemline became aware of the death on January 18 and disclosed it to the public on February 2.